Regulatory News:Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ...
PRESS RELEASE 2025 Full-year revenues increased by 18.4% year over year, reaching $2.63 billion. Net income attributable to Formula shareholders reached $606.5 million following the completion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results